Phase 3b/4 Safety Trial of Nivolumab Combined with Ipilimumab in Subjects with Previously Untreated Advanced or Metastatic RCC
Brief description of study
This is a phase 3b/4 trial evaluating a modified combination dosing regimen of Nivolumab combined with Ipilimumab in patients with clear-cell renal cell carcinoma.
Clinical Study Identifier: s16-02183
ClinicalTrials.gov Identifier: NCTs16-02183
If you are registered as a volunteer, please log in to contact the study team/express interest in this study.